Binding affinity

What is binding affinity? Binding affinity is how tightly a molecule, such as a peptide or drug, holds onto its binding partner, often a receptor. Think grip strength, not the result of the grip: affinity describes binding, while efficacy describes what happens after binding and selectivity asks what else the molecule grabs.

What does binding affinity mean?

The plain-English binding affinity meaning is the strength of a reversible molecular attachment. In the familiar lock-and-key picture, affinity is how firmly the key stays in the lock, not whether turning it opens a door. The drug affinity definition is deliberately narrow: one molecule, one binding partner, and the tendency of that pair to stay together rather than separate.

Researchers often describe receptor binding affinity with the equilibrium dissociation constant, written Kd. Kd is the free ligand concentration at which half the available receptor sites are occupied at equilibrium in a simple binding model. The pharmacology model described by Buchwald treats Kd as the binding-affinity term and keeps efficacy and downstream signal amplification separate.

The direction catches people out: a lower Kd means higher affinity. A ligand with a Kd of 1 nanomolar binds more tightly under the stated assay conditions than one with a Kd of 100 nanomolar. Kd is not a universal quality score, though. Temperature, pH, receptor state, assay design, and whether the system reached equilibrium can affect the measured value.

Is binding affinity the same as potency?

Binding affinity and potency are not the same measurement. Affinity asks how tightly a molecule binds; potency asks how much is needed to produce a stated effect in a particular experiment. A compound can bind tightly yet look less potent when it enters cells poorly, breaks down quickly, meets few receptors, or triggers a weak signal after binding.

That is the useful answer to affinity vs potency. Kd usually comes from a binding experiment. EC50 is the concentration producing half of the measured maximum effect, while IC50 is the concentration producing half of a measured inhibition. EC50 and IC50 depend on the assay and its biology; neither should be silently relabeled as Kd. Potency covers that functional side of the story.

How are affinity, efficacy, and selectivity different?

Affinity is how well a molecule binds, efficacy is what the bound molecule makes the receptor do, and selectivity is how much the molecule favors one target over others. These three properties can travel together, but pharmacology does not require them to. One good-looking number cannot stand in for the other two.

• Affinity: How tight is the grip on this target?
• Efficacy: Once bound, how much response can the ligand produce?
• Selectivity: How strongly does the ligand favor this target over other targets?

An agonist has efficacy because binding pushes the receptor toward a response. An antagonist can have enormous affinity and still produce no activating effect at all; the molecule occupies the receptor and blocks an agonist instead. Buchwald’s receptor model makes the split explicit by assigning antagonists zero intrinsic efficacy while treating affinity as its own parameter.

Selectivity needs comparisons. Saying a peptide has “high affinity” for receptor A tells you nothing about receptor B unless both were measured under suitable conditions. A molecule may grip its intended target tightly and grip an off-target almost as tightly. That is strong binding, poor selectivity, and a possible source of unwanted effects.

What does ipamorelin show about these terms?

Ipamorelin shows why the labels should stay in separate lanes. Ipamorelin is a receptor agonist that causes growth-hormone release, but the experiments used to describe its potency, efficacy, and hormone-release selectivity do not automatically provide a binding-affinity value. The endpoint printed beside a number matters more than the impressive number of zeros.

In the original pharmacology paper, ipamorelin activated a GHRP-like receptor and released growth hormone in rat pituitary cells, anesthetized rats, and conscious swine. The authors reported EC50 or ED50 values for growth-hormone release and Emax values for the maximum response. Those are functional potency and efficacy results, not direct Kd measurements of how tightly ipamorelin binds its receptor.

The same paper found that ipamorelin’s growth-hormone release was more selective than the comparison secretagogues’ hormone profile: ipamorelin did not raise adrenocorticotropic hormone or cortisol significantly above the response to growth-hormone-releasing hormone, even at much higher doses than its GH-release ED50. That is useful pharmacology, but it is still not a receptor-affinity panel. “Selective GH release” and “selective receptor binding” answer different questions.

What can binding affinity actually tell you?

Binding affinity can tell you whether a molecule is likely to occupy a particular target at a given concentration under defined experimental conditions. Binding affinity cannot, by itself, tell you whether a peptide improves symptoms, builds muscle, causes side effects, works in humans, or reaches that receptor after a real dose. Those claims sit on different evidence rungs.

This is where many tidy definitions stop too soon. A high-affinity result from a purified protein or cell assay is binding evidence, not a clinical outcome. Human benefit requires human outcome data; safety needs its own data; and receptor occupancy does not fill either gap. Honest evidence grading keeps laboratory mechanism, animal findings, and human trials labeled separately.

For anyone still asking what is binding affinity in a peptide profile, the clean answer is molecular grip strength. When reading a paper, ask four questions: What target was tested? Was the number Kd, Ki, EC50, IC50, or something else? What system produced it? What outcome was actually measured? That short check prevents the classic mistake of turning “sticks well to a receptor” into “works well in a person.” Affinity is useful. It is not a clinical verdict wearing a lab coat.